Clinical Trials Logo

Chorea clinical trials

View clinical trials related to Chorea.

Filter by:

NCT ID: NCT06312189 Enrolling by invitation - Chorea, Huntington Clinical Trials

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Start date: April 24, 2024
Phase: Phase 3
Study type: Interventional

This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.

NCT ID: NCT06259006 Not yet recruiting - Rheumatic Fever Clinical Trials

TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children

TREAT-SC
Start date: May 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out whether an early three-day course of an oral steroid medication (dexamethasone) can improve the physical and mental recovery and wellbeing for children with Sydenham's chorea. Sydenham's chorea is a condition that impacts approximately 12% of children with acute rheumatic fever. It is caused by inflammation in the brain following an abnormal immune response to Group A streptococcus bacterial infection. Sydenham's chorea is a movement disorder that causes children's faces, hands, and feet to move quickly and uncontrollably, and can also affect mood and concentration. The physical recovery from Sydenham's chorea can take two to six months but the mental recovery (e.g. mood and concentration) can take longer to resolve. Sydenham's chorea remains endemic in Māori, Pacific Islander, Aboriginal and Torres Strait Islander children in New Zealand and Australia. There is limited evidence to direct treatment of Sydenham's chorea, and clinical practice differs widely around the world. Dexamethasone is an oral steroid which targets the abnormal immune response and successfully treats other immune-mediated brain disorders, with good tolerability. TREAT-SC is a randomized, double-blinded, placebo-controlled trial which will investigate whether a three day course of oral dexamethasone safely and effectively treats the movement disorder and psychiatric symptoms of Sydenham's chorea. The trial will recruit 80 participants from study sites in Australia and New Zealand.

NCT ID: NCT05475483 Active, not recruiting - Huntington Chorea Clinical Trials

Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Start date: August 2, 2022
Phase: Phase 2
Study type: Interventional

Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.

NCT ID: NCT04400331 Active, not recruiting - Chorea, Huntington Clinical Trials

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Start date: September 18, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

NCT ID: NCT04244513 Recruiting - Huntington Disease Clinical Trials

Deep Brain Stimulation Treatment for Chorea in Huntington's Disease

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

1. Evaluating therapeutic effects of globus pallidus internus (GPi) deep brain stimulation (DBS) on Huntington's disease (HD) patients with chorea; 2. Explore the relationship between brain network conditions and DBS efficacy in HD patients 3. Explore the effect of different programmed parameters on the treatment of patients with DBS

NCT ID: NCT04201834 Completed - Huntington Disease Clinical Trials

Risperidone for the Treatment of Huntington's Disease Involuntary Movements

Start date: August 13, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly used in clinical practice to treat chorea, however, it has not been approved by the Food and Drug Administration (FDA) to treat chorea. This study will examine 1) whether the investigators see MRI changes with risperidone treatment and 2) whether sensors applied to the participants body can measure chorea and detect changes in chorea.

NCT ID: NCT04102579 Completed - Chorea, Huntington Clinical Trials

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

KINECT-HD
Start date: November 13, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.

NCT ID: NCT04084977 Enrolling by invitation - Strep Throat Clinical Trials

Dopaminergic Receptors in Sydenham's Chorea

Start date: July 1, 2016
Phase:
Study type: Observational

Sydenham's chorea (SC) is a post-streptococcal, neuropsychiatric disorder associated with anti-neuronal antibodies. The investigators demonstrated elevated anti-D1-receptor (D1R) and anti-D2-receptor (D2R) antibodies titers compared to controls using ELISA. Similarly, the investigators found antibodies to surface D2R in neuropsychiatric, autoimmune disorders, including SC using cell-based assays. The investigators hypothesize that these autoantibodies cause neuropsychiatric symptoms by inducing intracellular signaling changes resulting in altered dopaminergic neurotransmission. To check this, the investigators will test whether sera from patients with SC alter dopaminergic signaling pathways. The investigators will examine sera from 30 SC patients with active symptoms and 30 age-matched healthy controls. Patients with SC will be assessed for severity of neuropsychiatric symptoms using UFMG Sydenham's Chorea Rating Scale. Controls with evidence of streptococcal infections or autoimmune disorders will be excluded. Sera will be examined for anti-D1R and anti-D2R antibodies. Signaling studies will assess sera impact on 1) calcium/calmodulin-dependent protein kinase II activity in human neuronal cells. 2) dopamine D1/D2 receptors signaling using cAMP assays in transfected cell lines. The investigators will examine the correlation between modified signaling and clinical symptoms.

NCT ID: NCT03575676 Completed - Huntington's Chorea Clinical Trials

Efficacy and Safety of SOM3355 in Huntington's Disease Chorea

Start date: August 8, 2018
Phase: Phase 2
Study type: Interventional

Phase IIa study to evaluate the efficacy and safety of SOM3355 in chorea movements associated with Huntington's disease

NCT ID: NCT01897896 Completed - Clinical trials for Chorea Associated With Huntington Disease

Alternatives for Reducing Chorea in Huntington Disease

ARC-HD
Start date: November 12, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.